This research offers significant findings on the impact of a treatment combination using anti-CTLA-4 and anti-PD-1 antibodies on vascular and systemic inflammation caused by myeloid cells in patients with melanoma, as well as in mice with hyperlipidemia (59). Here, CTLA4 is linked to melanoma.